Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Core Insights - Aptose Biosciences Inc. has regained compliance with Nasdaq's minimum bid price requirement, with the closing bid price of its common shares being $1.00 or greater for ten consecutive business days [2] - The company is still not in compliance with the $2.5 million shareholders equity requirement but is operating under an exception granted by the Hearing Panel, allowing additional time to regain compliance [2] - Aptose is focused on developing precision oncology therapies, particularly for hematology, with its lead compound tuspetinib (TUS) being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) [3] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company dedicated to developing precision medicines for unmet medical needs in oncology [3] - The company's pipeline includes small molecule cancer therapeutics aimed at providing single-agent efficacy and enhancing the effectiveness of other anti-cancer therapies without overlapping toxicities [3] - Tuspetinib (TUS) is an oral kinase inhibitor that has shown activity as both a monotherapy and in combination therapy for patients with relapsed or refractory AML [3]